| Ytd | 41.19% | |
| 1y | -6.52% |
| Open | 10.40 | Prev Close | 10.42 | Low | 10.10 | High | 10.62 | Mkt Cap | 299.10M |
| Vol | 149.43K | Avg Vol | 291.87K | EPS | -5.80 | P/E | N/A | Forward P/E | -5.54 |
| Beta | N/A | Short Ratio | 15.83 | Inst. Own | 27.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 7.75 | 200-d Avg | 7.69 | 1yr Est | 38.17 |
RNAC News
FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “
CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthe
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains
BTIG analyst Julian Harrison reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maint
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Des
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology c
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC)
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.46) per share which missed the
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
Cantor Fitzgerald analyst Kristen Kluska upgrades Cartesian Therapeutics (NASDAQ:RNAC) from Neutr
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.39) per share which missed the
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the
Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalim
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC)
Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for
BTIG analyst Julian Harrison maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology c
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.38) per share which missed the
U.S. stock futures were volatile on Wednesday after the equities reversed gains on Tuesday following
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed t
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company re
The Dow Jones index closed higher by around 75 points on Monday. When insiders purchase or sell shar